Research programme: IL-17/IL-23 bispecific antibody - Bristol-Myers Squibb

Drug Profile

Research programme: IL-17/IL-23 bispecific antibody - Bristol-Myers Squibb

Alternative Names: IL-17/IL-23 biAb

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bristol-Myers Squibb
  • Class Bispecific antibodies
  • Mechanism of Action Interleukin 17 modulators; Interleukin 23 modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Immunological disorders

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Immunological-disorders in USA (Parenteral)
  • 31 Dec 2012 Preclinical trials in Immunological disorders in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top